|
Market Cap (20-May) $2,216,115,200 (333rd) |
Close (30-Jun) $1.14 |
Volume (30-Jun) 2,606,681 |
Shortsold (5-May) 72,824,861 (5.70%) (40th) |
|
52w High $3.37 |
52w Low $0.88 |
P/E 454.55 |
EPS -0.14 |
MSB released this announcement to the ASX on 17 January 2022, 18:02. The announcement is not marked as price sensitive, and is 24 page(s) in length and 543.81kb in size.
You can view all announcements from MSB and see how they appear on a price chart on the announcements page.
At the date of this announcement, MSB was 9.520% short sold according to ASIC data. It was ranked the 6th most shorted stock on the ASX. It remains ranked 40th as of the latest reported data (05 May 2025).
| Other Recent Announcements from MSB | |
|---|---|
| Change of Director's Interest Notice | 13 June 2023, 8:56 |
| Mesoblast Director Appointed to Strategic Advisory Role | 5 June 2023, 9:41 |
| MSB Reports Q3 Financial Results and Operational Highlights | 26 May 2023, 8:32 |
| Appendix 3G, Appendix 3H and Appendix 3Y | 17 January 2022, 18:02 |
| 36-Month Results of Phase 3 Trial in Chronic Low Back Pain | 12 January 2022, 10:05 |
| Biotech Showcase 2022 Presentation | 12 January 2022, 9:56 |
| Prospectus for Warrants Related to Oaktree Debt Refinance | 6 January 2022, 18:35 |
You must be logged in to post a reply.
Mesoblast 